---

$15.61

+0.1290 ( +0.83% ) 905.1K

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2024-08-01	Sale	-5760.00	Ring Christine
2024-08-01	Sale	-3377.00	van Houte Hans
2024-07-30	Sale	-1924.00	Ring Christine
2024-07-30	Sale	-2886.00	van Houte Hans
2024-07-30	Sale	-3207.00	Hansen Gwenn
2024-07-18	Sale	-54027.00	Kunkel Lori Anne
2024-07-01	Sale	-5760.00	Ring Christine
2024-06-20	Sale	-20000.00	van Houte Hans
2024-06-13	Sale	-1864.00	Ring Christine
2024-06-12	Sale	-1900.00	Ring Christine